Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.

[Back to Overview]  [IACM Homepage]

TitleEfficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents - An observational, longitudinal study
Author(s)Hausman-Kedem M, Menascu S, Kramer U
Journal, Volume, IssueBrain Dev. [Epub ahead of print]
Major outcome(s)A cannabis extract with THC and CBD reduced seizures in epilepsy

The objective of this observational study was to evaluate the efficacy of medical cannabis for the treatment of refractory epilepsy. Fifty-seven patients (age 1-20&#8239;years) with epilepsy of various etiologies were treated with Cannabis oil extract (CBD/THC ratio of 20:1) for at least 3&#8239;months (Median follow up time-18&#8239;months). Forty-Six Patients were included in the efficacy analysis. Average CBD dose was11.4&#8239;mg/kg/d. Twenty-six patients (56%) had &#8804;50% reduction in mean monthly seizure frequency. There was no statistically significant difference in response rate among various epilepsy etiologies, and cannabis strain used. Younger age at treatment onset (<10&#8239;years) and higher CBD dose (>11&#8239;mg/kg/d) were associated with better response to treatment. Adverse reactions were reported in 46% of patients and were the main reason for treatment cessation. Our results suggest that adding CBD-enriched cannabis extract to the treatment regimen of patients with refractory epilepsy may result in a significant reduction in seizure frequency according to parental reports. Randomized controlled trials are necessary to assess its true efficacy.

Duration (days)
ParticipantsFifty-seven patients (age 1-20 years) with epilepsy of
DesignOpen study
Type of publicationMedical journal
Address of author(s)
Full text

[Back to Overview]  [IACM Homepage]